Kymera Therapeutics (KYMR) Stock Price, News & Analysis

Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $28.39 to $30.96
• 50-Day Range: $21.05 to $35.28
• 52-Week Range: $19.45 to $53.27
• Volume: 730,110 shs
• Average Volume: 560,584 shs
• Market Capitalization: $1.94 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.36
• Consensus Rating: Moderate Buy

Kymera Therapeutics Stock Analysis - MarketRank™

Kymera Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 822nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kymera Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.79) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kymera Therapeutics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kymera Therapeutics is -12.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kymera Therapeutics has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.52% of the float of Kymera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kymera Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Kymera Therapeutics has recently decreased by 7.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kymera Therapeutics does not currently pay a dividend.

Dividend Growth

Kymera Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.52% of the float of Kymera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kymera Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Kymera Therapeutics has recently decreased by 7.76%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.52

News Sentiment

Kymera Therapeutics has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Kymera Therapeutics this week, compared to 5 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $324,567.00 in company stock.

Percentage Held by Insiders

15.82% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

KYMR Stock Analysis - Frequently Asked Questions

How have KYMR shares performed this year?

Kymera Therapeutics' stock was trading at $40.23 at the beginning of 2025. Since then, KYMR shares have decreased by 27.6% and is now trading at $29.11.
View the best growth stocks for 2025 here.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced its earnings results on Thursday, February, 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.12. The business earned $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative trailing twelve-month return on equity of 24.96%.
Read the conference call transcript.

When did Kymera Therapeutics IPO?

Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Kymera Therapeutics' major shareholders?

Top institutional investors of Kymera Therapeutics include Jennison Associates LLC (0.85%), Massachusetts Financial Services Co. MA (0.65%), TD Asset Management Inc (0.31%) and Universal Beteiligungs und Servicegesellschaft mbH (0.13%). Insiders that own company stock include Venture Fund X LP Atlas, Bvf Partners L P/Il, Bruce Booth, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Jeremy G Chadwick, Joanna Horobin and Jeffrey W Albers.
View institutional ownership trends.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 5/08/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYMR
• CIK: 1815442
• Web: www.kymeratx.com
• Phone: 857-285-5300
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.36
• High Stock Price Target: $74.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +93.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.87
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-146,960,000.00
• Net Margins: -191.26%
• Pretax Margin: -191.26%
• Return on Equity: -24.96%
• Return on Assets: -20.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.55
• Quick Ratio: 8.55

Sales & Book Value

• Annual Sales: $47.07 million
• Price / Sales: 40.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.12 per share
• Price / Book: 4.09

Miscellaneous

• Outstanding Shares: 65,117,000
• Free Float: 54,519,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 2.18